University of South Alabama

c-Myb as a Biomarker and Therapeutic in Prostate Cancer



Prostate cancer is the most frequently diagnosed cancer in men and is an extremely heterogeneous disease. Reliable diagnosis of prostate cancer is a critical component of treatment, and reducing the diagnosis time has been shown to result in a better prognosis of many patients. Although the prostate specific antigen (PSA) test is a standard diagnostic technique, there is considerable value in identifying more reproducible and reliable markers with greater discriminatory power than ones that already exist. The PSA test is controversial in that it sometimes leads to false positive results or detection of tumors that will not be fatal in the lifetime of the patient, resulting in impaired quality of lives for men who are misdiagnosed. Having additional non-invasive, molecular tests that correlate with PSA levels will add significant value to the current standard of care.



Inventors at the University of South Alabama have identified c-Myb protein expression as an innovative and improved diagnostic marker for immunohistochemical detection of prostate cancer from biopsy samples. Based on experiments utilizing established cell lines, inventors have demonstrated a linear relationship between levels of c-Myb and prostate specific antigen (PSA), the current standard for prostate cancer detection which is also highly expressed in androgen independent, hormone refractory cancers. Modulation of c-Myb results in changes in expression of c-Myc and CXCR4, genes previously implicated in prostate carcinogenesis. c-Myb expression is associated with chemoresistance such that increased c-Myb expression positively correlates with greater resistance to the certain chemotherapeutic drugs and greater cell viability in experiments performed in prostate cancer cell lines. These experiments together demonstrate a significant role for c-Myb overexpression in the progression of androgen independent tumors in addition to its role as a biomarker making it a potentially robust diagnostic marker.



•  Diagnostic marker of prostate cancer

•  Targeted treatment based on c-Myb expression

•  Reduced number of false positive results

•  Increased quality of life for patients



Patent Issued


Download a PDF version of the description

Patent Information:
For Information, Contact:
Andrew Byrd
University of South Alabama
Ajay Singh
Seema Singh
Sanjeev Srivastava